Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies

Human Antibodies

Volumn 19, Issue 1, 2010, Pages 7-13

  Tran, L ^a   Baars, J W ^b   Aarden, L ^c   Beijnen, J H ^a,d   Huitema, A D R ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c CENTRAL LABORATORY   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; LOMUSTINE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTIBODY; ANTINEOPLASTIC AGENT; CARMUSTINE; CD20 ANTIGEN; MONOCLONAL ANTIBODY; VIDARABINE; VINDESINE;

ADULT; AGED; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HALF LIFE TIME; HODGKIN DISEASE; HUMAN; LYMPHATIC LEUKEMIA; MAINTENANCE THERAPY; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; PATIENT COMPLIANCE; PHARMACODYNAMICS; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CELL; ANALOGS AND DERIVATIVES; BLOOD; DRUG ADMINISTRATION; DRUG COMBINATION; IMMUNOLOGY; LYMPHOMA, NON-HODGKIN; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; CARMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISONE; TREATMENT OUTCOME; VIDARABINE; VINCRISTINE; VINDESINE;

EID: 77953727888     PISSN: 10932607     EISSN: None     Source Type: Journal    
DOI: 10.3233/HAB-2010-0215     Document Type: Article

References (36)

1. K.C. Anderson, M.P. Bates, B.L. Slaughenhoupt, G.S. Pinkus, S.F. Schlossman and L.M. Nadler, Expression of humanBcellassociated antigens on leukemias and lymphomas: a model of human B cell differentiation, Blood 63 (1984), 1424-1433.
2. D.G. Maloney, A.J. Grillo-Lopez, D.J. Bodkin, C.A. White, T.M. Liles, I. Royston, C. Varns, J. Rosenberg and R. Levy, IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma, J Clin Oncol 15 (1997), 3266-3274. (Pubitemid 27419340)
3. M.E. Reff, K. Carner, K.S. Chambers, P.C. Chinn, J.E. Leonard, R. Raab, R.A. Newman, N. Hanna and D.R. Anderson, Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20, Blood 83 (1994), 435-445.
4. P. McLaughlin, A.J. Grillo-Lopez, B.K. Link, R. Levy, M.S. Czuczman, M.E.Williams, M.R. Heyman, I. Bence-Bruckler, C.A. White, F. Cabanillas, V. Jain, A.D. Ho, J. Lister, K.Wey, D. Shen and B.K. Dallaire, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program, J Clin Oncol 16 (1998), 2825-2833.
5. J. Pijpe, G.W. van Imhoff, F.K. Spijkervet, J.L. Roodenburg, G.J. Wolbink, K. Mansour, A. Vissink, C.G. Kallenberg and H. Bootsma, Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study, Arthritis Rheum 52 (2005), 2740-2750.
6. K. Tobinai, Y. Kobayashi, M. Narabayashi, M. Ogura, Y. Kagami, Y. Morishima, T. Ohtsu, T. Igarashi, Y. Sasaki, T. Kinoshita and T. Murate, Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group, Ann Oncol 9 (1998), 527-534.
7. N.L. Berinstein, A.J. Grillo-Lopez, C.A. White, I. Bence- Bruckler, D. Maloney, M. Czuczman, D. Green, J. Rosenberg, P. McLaughlin and D. Shen, Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma, Ann Oncol 9 (1998), 995-1001.
8. Y.O. Huh, M.J. Keating, H.L. Saffer, I. Jilani, S. Lerner and M. Albitar, Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia, Am J Clin Pathol 116 (2001), 437-443.
9. J.C. Byrd, T. Murphy, R.S. Howard, M.S. Lucas, A. Goodrich, K. Park, M. Pearson, J.K. Waselenko, G. Ling, M.R. Grever, A.J. Grillo-Lopez, J. Rosenberg, L. Kunkel and I.W. Flinn, Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity, J Clin Oncol 19 (2001), 2153-2164.
10. T. Manshouri, K.A. Do, X. Wang, F.J. Giles, S.M. O'Brien, H. Saffer, D. Thomas, I. Jilani, H.M. Kantarjian, M.J. Keating and M. Albitar, Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance, Blood 101 (2003), 2507-2513.
11. C.W. Damen, E.R. de Groot, M. Heij, D.S. Boss, J.H. Schellens, H. Rosing, J.H. Beijnen and L.A. Aarden, Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma, Anal Biochem 391 (2009), 114-120.
12. G.M. Bartelds, C.A. Wijbrandts, M.T. Nurmohamed, S. Stapel, W.F. Lems, L. Aarden, B.A. Dijkmans, P.P. Tak and G.J. Wolbink, Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis, Ann Rheum Dis 66 (2007), 921-926.
13. C.M. Ng, R. Bruno, D. Combs and B. Davies, Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial, J Clin Pharmacol 45 (2005), 792-801.
14. N.L. Berinstein, A.J. Grillo-Lopez, C.A. White, I. Bence- Bruckler, D. Maloney, M. Czuczman, D. Green, J. Rosenberg, P. McLaughlin and D. Shen, Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma, Ann Oncol 9 (1998), 995-1001.
15. P. McLaughlin, A.J. Grillo-Lopez, B.K. Link, R. Levy, M.S. Czuczman, M.E.Williams, M.R. Heyman, I. Bence-Bruckler, C.A. White, F. Cabanillas, V. Jain, A.D. Ho, J. Lister, K.Wey, D. Shen and B.K. Dallaire, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program, J Clin Oncol 16 (1998), 2825-2833.
16. N.L. Berinstein, A.J. Grillo-Lopez, C.A. White, I. Bence- Bruckler, D. Maloney, M. Czuczman, D. Green, J. Rosenberg, P. McLaughlin and D. Shen, Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma, Ann Oncol 9 (1998), 995-1001.
17. P. McLaughlin, A.J. Grillo-Lopez, B.K. Link, R. Levy, M.S. Czuczman, M.E.Williams, M.R. Heyman, I. Bence-Bruckler, C.A. White, F. Cabanillas, V. Jain, A.D. Ho, J. Lister, K.Wey, D. Shen and B.K. Dallaire, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program, J Clin Oncol 16 (1998), 2825-2833.
18. D. Dayde, D. Ternant, M. Ohresser, S. Lerondel, S. Pesnel, H. Watier, A. Le Pape, P. Bardos, G. Paintaud and G. Cartron, Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20, Blood 113 (2009), 3765-3772.
19. N.A. Johnson, M. Boyle, A. Bashashati, S. Leach, A. Brooks- Wilson, L. H. Sehn, M. Chhanabhai, R.R. Brinkman, J.M. Connors, A.P. Weng and R.D. Gascoyne, Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival, Blood 113 (2009), 3773-3780.
20. M.B. Regazzi, I. Iacona, M.A. Avanzini, L. Arcaini, G. Merlini, V. Perfetti, F. Zaja, M. Montagna, E. Morra and M. Lazzarino, Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings, Ther Drug Monit 27 (2005), 785-792.
21. J. Mangel, R. Buckstein, K. Imrie, D. Spaner, E. Franssen, P. Pavlin, A. Boudreau, N. Pennell, D. Combs and N.L. Berinstein, Pharmacokinetic study of patients with follicular ormantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation, Ann Oncol 14 (2003), 758-765.
22. H. Blasco, E. Chatelut, I.B. de Bretagne, N. Congy-Jolivet and C. Le Guellec, Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma, Fundam Clin Pharmacol (2009).
23. T. Manshouri, K.A. Do, X. Wang, F.J. Giles, S.M. O'Brien, H. Saffer, D. Thomas, I. Jilani, H.M. Kantarjian, M.J. Keating and M. Albitar, Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance, Blood 101 (2003), 2507-2513.
24. S.M. O'Brien, H. Kantarjian, D.A. Thomas, F.J. Giles, E.J. Freireich, J. Cortes, S. Lerner and M.J. Keating, Rituximab dose-escalation trial in chronic lymphocytic leukemia, J Clin Oncol 19 (2001), 2165-2170. (Pubitemid 32366970)
25. S.M. O'Brien, H.M. Kantarjian, J. Cortes, M. Beran, C.A. Koller, F.J. Giles, S. Lerner and M. Keating, Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia, J Clin Oncol 19 (2001), 1414-1420.
26. J.C. Byrd, T. Murphy, R.S. Howard, M.S. Lucas, A. Goodrich, K. Park, M. Pearson, J.K. Waselenko, G. Ling, M.R. Grever, A.J. Grillo-Lopez, J. Rosenberg, L. Kunkel and I.W. Flinn, Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity, J Clin Oncol 19 (2001), 2153-2164.
27. J.C. Byrd, T. Murphy, R.S. Howard, M.S. Lucas, A. Goodrich, K. Park, M. Pearson, J.K. Waselenko, G. Ling, M.R. Grever, A.J. Grillo-Lopez, J. Rosenberg, L. Kunkel and I.W. Flinn, Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity, J Clin Oncol 19 (2001), 2153-2164.
28. M. Ghielmini, S.F. Schmitz, S.B. Cogliatti, G. Pichert, J. Hummerjohann, U.Waltzer, M.F. Fey, D.C. Betticher, G. Martinelli, F. Peccatori, U. Hess, E. Zucca, R. Stupp, T. Kovacsovics, C. Helg, A. Lohri, M. Bargetzi, D. Vorobiof and T. Cerny, Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule, Blood 103 (2004), 4416-4423.
29. M.H. Van Oers, A. Hagenbeek, M. Van Glabbeke and I. Teodorovic, Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial - Intergroup Collaborative Study, Ann Hematol 81 (2002), 553-557.
30. J.D. Hainsworth, S. Litchy, J.H. Barton, G.A. Houston, R.C. Hermann, J.E. Bradof and F.A. Greco, Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network, J Clin Oncol 21 (2003), 1746-1751.
31. W. Brugger, J. Hirsch, F. Grunebach, R. Repp, P. Brossart, W. Vogel, H.G. Kopp, M.G. Manz, M. Bitzer, G. Schlimok, M. Kaufmann, A. Ganser, K. Fehnle, M. Gramatzki and L. Kanz, Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study, Ann Oncol 15 (2004), 1691-1698.
32. R.J. Looney, J.H. Anolik, D. Campbell, R.E. Felgar, F. Young, L.J. Arend, J.A. Sloand, J. Rosenblatt and I. Sanz, B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab, Arthritis Rheum 50 (2004), 2580-2589.
33. J. Pijpe, G.W. van Imhoff, F.K. Spijkervet, J.L. Roodenburg, G.J. Wolbink, K. Mansour, A. Vissink, C.G. Kallenberg and H. Bootsma, Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study, Arthritis Rheum 52 (2005), 2740-2750.
34. J.C. Edwards, L. Szczepanski, J. Szechinski, A. Filipowicz- Sosnowska, P. Emery, D.R. Close, R.M. Stevens and T. Shaw, Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis, N Engl J Med 350 (2004), 2572-2581. (Pubitemid 38758544)
35. P. McLaughlin, A.J. Grillo-Lopez, B.K. Link, R. Levy, M.S. Czuczman, M.E.Williams, M.R. Heyman, I. Bence-Bruckler, C.A. White, F. Cabanillas, V. Jain, A.D. Ho, J. Lister, K.Wey, D. Shen and B.K. Dallaire, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program, J Clin Oncol 16 (1998), 2825-2833.
36. N.L. Berinstein, A.J. Grillo-Lopez, C.A. White, I. Bence- Bruckler, D. Maloney, M. Czuczman, D. Green, J. Rosenberg, P. McLaughlin and D. Shen, Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma, Ann Oncol 9 (1998), 995-1001.